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Abstract: Disease exacerbations are an important aspect of COPD, because they affect its course 
and are associated with higher lung function decline. On the other hand, data obtained by biopsies 
have demonstrated that the progression of COPD is related to an increasing impairment of small 
airways. We sought to evaluate the small airway impairment (FEF25–75) in two groups of COPD 
patients (each group had 37 subjects) in relation to the frequency of exacerbations and the effective-
ness of treatment with tiotropium bromide on the small airway impairment. The mean number of 
exacerbations was 3.6/year and 1.38/year in frequent and in infrequent exacerbators, respectively 
(p   0.001). The mean value of FEF25–75 at baseline was 624 mL and 865 mL in frequent and 
in infrequent exacerbators respectively (p = 0.002). The changes in respiratory parameters ver-
sus baseline showed increases in mean FEV1, FVC, and FEF25–75 in both groups but only the 
increase in FEF25–75 in frequent exacerbators was statistically signiﬁ  cantly (p = 0.013). During 
the 3-month period of the study the mean number of exacerbations was 0.66 in frequent and 0.12 
in infrequent exacerbators. These ﬁ  ndings indicate that COPD patients with frequent exacerbations 
have a higher impairment of small airways. Treatment with tiotropium in COPD subjects with 
frequent exacerbations proved to be effective in improving small airway impairment.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major health problem. It is char-
acterized by a progressive impairment of lung function (Barnes 2000) and leads to 
inability and mortality, which are projected to increase their burden in future (Murray 
and Lopez 1997). This makes the treatment strategies for COPD very important, cur-
rently stated as mainly smoking cessation, drug therapy, and pulmonary rehabilitation 
(Sutherland and Cherniak 2004).
An important aspect of COPD is the exacerbations, which occur regardless of the 
stage of disease according to GOLD classiﬁ  cation (Pauwels et al 2004; Rabe et al 2007), 
and is currently deﬁ  ned as “... a sustained worsening of the patient’s symptoms from 
his or her usual stable state that is beyond normal day to day variations, and is acute in 
onset. Commonly reported symptoms are worsening breathlessness, cough, increased 
sputum production and change in sputum color. The change in these symptoms often 
necessitates a change in medication.” (The National Collaborating Centre for Chronic 
Conditions 2004).
Exacerbations clearly affect the course of the disease, since their frequency is 
related to lung function decline (Donaldson et al 2002). In particular, data obtained by 
biopsies demonstrated that the progression of COPD is associated with an increasing 
impairment of small airways which is strongly related to inﬁ  ltration of inﬂ  ammatory 
cells in airways walls and accumulation of exudate in the lumen (Hogg et al 2004).International Journal of COPD 2008:3(1) 124
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Tiotropium bromide, a second-generation anticholinergic 
agent, showed a favorable inﬂ  uence on the rate of exacerba-
tions in COPD patients (Brusasco et al 2003).
We sought to evaluate 1) the small airway impairment 
in COPD patients with frequent or infrequent exacerbations 
and 2) the effect of treatment with tiotropium bromide on 
small airway impairment.
Methods
Patients
Seventy-six subjects referred to the Unit of Pulmonary 
Rehabilitation of the ICP Hospital in Milan were included 
in the study. To be included, patients had to be in a stable 
condition, free from exacerbations for at least 2 months, clas-
siﬁ  ed in GOLD stage 2–4 according to FEV1 values, and on 
treatment only with inhaled drugs such as long-acting beta2-
agonists (LABA) or inhaled corticosteroids (IC), plus short 
acting beta2-agonists (SABA) as needed. The patients were 
divided according to the frequency of exacerbations: patients 
with more than 2 exacerbations per year formed group A; 
patients with up to 2 exacerbations per year formed group 
B. In all patients, treatment with tiotropium, at the currently 
recommended dose of 18 µg once daily, was added. For 
drugs already used, the inhalation technique was optimized 
by employing spacer devices, if they had not been already 
introduced. Patients initiating treatment with tiotropium 
were trained to use the dry powder inhaler device.
Pulmonary function was measured at baseline and after 
3 months of treatment. Patients were instructed to recognize 
and report any exacerbation during the study.
Pulmonary function
The FEV1, the FVC, the expiratory ﬂ  ows at low volumes 
(FEF25, 50, and 75), the FRC, and the residual volume (RV) 
were measured by an automated pulmonary function testing 
center (6200 Autobox DL, Sensor Medics, Yorba Linda, CA, 
USA) in accordance with recognized standards (American 
Thoracic Society 1995). Variables were measured at baseline 
and after the 3-month treatment. Prior to measurement SABA 
were discontinued for at least 8 hours, LABA and IC for at 
least 12 hours, and, at the second measurement, tiotropium 
for 24 hours.
Statistical analysis
Differences in the number of exacerbations and in pulmonary 
function in relation to the intervention in patients in groups 
A and B were analyzed by the Mann Whitney U test, setting 
a p value lower than 0.05 as signiﬁ  cant.
Results
Two out of the 76 patients included in the study did not 
perform the second plethysmography (1 in group A and 
1 in group B) and were not considered in the analysis. 
Table 1 shows the characteristics of the 74 patients, 37 in 
each group.
The mean number of exacerbations was 3.6 ± 0.64/year 
in group A and 1.38 ± 0.59/year in group B (p   0.001). The 
baseline mean value of FEF25–75 was 624 ± 418 mL in group 
A and 865 ± 372 mL in group B (p = 0.002).
Changes in each respiratory parameter versus baseline 
are reported in Table 2. There were increases in mean 
FEV1, FVC, and FEF25–75 in both groups, but only the 
increase in FEF25–75 in group A was statistically signiﬁ  cant 
(p = 0.013).
During the 3-month study period the mean number of 
exacerbations was 0.66 ± 0.18 in group A and 0.12 ± 0.05 
in group B.
Discussion
Exacerbations are a serious concern in COPD. They repre-
sent an important cause of hospitalization and mortality and 
consume great medical resources (Garcia-Aymerich et al 
2001; Rabe et al 2003). Frequent exacerbations are associ-
ated with a higher lung function decline. A longitudinal 
study with a 4-year follow-up reported that COPD patients 
with frequent exacerbations (median rate of 4.2/year) had 
a higher decline of FEV1 (especially in persistent smokers) 
than those with infrequent exacerbation (median rate of 1.9 
per year): FEV1 decline was 40 mL/year versus 32 mL/year 
in patients with frequent and infrequent exacerbations, 
respectively (Donaldson et al 2002). This conﬁ  rmed the 
results of a previous study on COPD patients with exac-
erbations, which showed a higher FEV1 decline in current 
smokers than in ex-smokers (Kanner et al 2001) and draws 
the attention to the importance of the underlying damage 
to the airways.
Table 1 Characteristics of patients at inclusion
Group A  B
Gender  22 males, 15 females  23 males, 14 females
Mean age (range)  71.7 years (55–85)  72.1 years (56–88)
Mean duration of COPD  13.8 years  12.3 years
Active smoking history  29/37  31/37
Use of IC  30/37  27/37
Use of LABA  20/37  23/37
Mean FEV1 (mL)  1191 ± 185 1249  ± 373
Mean FVC (mL)  2212 ± 803 2433  ± 649
Abbreviations: IC, inhaled corticosteroids; LABA, long-acting beta2-agonists.International Journal of COPD 2008:3(1) 125
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A signiﬁ  cant advance in the knowledge of the kind of 
damage in COPD was achieved by the study of Hogg et al. 
These authors investigated the progression of the disease 
in different COPD stages by means of lung biopsies. They 
found that the grade of wall thickness of the small airways, 
resulting from inﬁ  ltration of inﬂ  ammatory cells and structural 
changes, was correlated with disease severity, as assessed by 
FEV1 values (Hogg et al 2004). It is somewhat surprising that, 
following such observation, measurement of small airway 
parameters in COPD patients has been almost overlooked.
We designed the present study to investigate the changes 
in small airway obstruction in patients with COPD with 
frequent or infrequent exacerbations undergoing treatment 
with tiotropium. We chose tiotropium because of its effec-
tiveness, which was clearly demonstrated by a Cochrane 
meta-analysis (Barr et al 2005), by its ability to reduce the 
number of exacerbations (Brusasco et al 2003), and by its 
capacity to improve pulmonary function (Casaburi et al 2000; 
Cazzola et al 2005; Incorvaia et al 2007) including small 
airway parameters (Incorvaia et al 2007). In particular, such 
effects had already been detected after short-term treatment 
and are likely to be linked to the ability of the drug to reach 
the deeper airways and to interact with muscarinic receptors, 
particularly with those positioned in the smooth muscle of 
small airways (Barnes 1993). The efﬁ  ciency of the speciﬁ  c 
dry powder inhaler device may possibly help patient perfor-
mance in such effects (Dahl et al 2003).
Our ﬁ  ndings indicate that frequent exacerbators have 
signiﬁ  cantly lower FEF25–75 (the main functional parameter 
of small airways) values compared to infrequent exacerbatiors. 
The mean number of exacerbations was 3.6 ± 0.64/year in 
frequent and 1.38 ± 0.59/year in infrequent exacerbators, data 
comparable to those reported by Donaldson et al in the study 
on association between lung function decline and frequent 
exacerbations (Donaldson et al 2002). Treatment with tiotro-
pium improved pulmonary function parameters, including 
FEV1, FVC, and FEF25–75, but only the increase in FEF25–
75 mean value in frequent exacerbators was statistically 
signiﬁ  cant. Otherwise these subjects had a signiﬁ  cantly lower 
mean baseline value, indicating a more severe impairment in 
small airways, compared with infrequent exacerbators. Both 
groups showed a decrease in rate of exacerbations during 
the 3-month study period. We planned such a trial duration 
because as our patients were undergoing pulmonary rehabilita-
tion we needed to avoid possible bias on exacerbations by this 
treatment, as observed in a previous study (Riario-Sforza et al 
2005). On the other hand, the ability of tiotropium to reduce 
the rate of COPD exacerbations has already been reported 
in a 6-month, multicenter, controlled study, which detected 
a signiﬁ  cantly lower number of exacerbations in tiotropium 
than in placebo-treated patients (Brusasco et al 2003). The 
nature of such an effect is not easy to explain, since tiotro-
pium is a bronchodilating and not a antinﬂ  ammatory agent, 
as are IC, which is known to reduce exacerbations (Phua and 
Macintyre 2007). A recent study evaluated the effect of tiotro-
pium on inﬂ  ammatory markers in sputum and in serum and 
on exacerbations in COPD: a 52% reduction in exacerbation 
frequency was observed, compared with no signiﬁ  cant change 
in inﬂ  ammatory markers (Powrie et al 2007).
Our study, conducted on patients already treated with IC, 
who received tiotropium as an additional agent, showed that 
tiotropium may further reduce the number of exacerbations. 
Still, the major observation of the present study is that COPD 
patients with frequent exacerbations have a higher impair-
ment of small airways, as assessed by measurement of their 
functional parameter FEF25–75, and that treatment with 
tiotropium can signiﬁ  cantly improve this parameter.
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